GlaxoSmithKline

UNDER EVALAUATION (SITE QUALIFICATION VISIT 07/22/2026) VIGILANT: A multi-center, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with Type 2 inflammation.